An International Reputation for Cardiac Excellence
Stanford is recognized worldwide as a pioneering center for heart
transplants. Dr. Norman Shumway and his colleagues developed the
experimental basis for transplants in their early work, which then
paved the way for the first adult heart transplant in the U.S. at
Stanford in 1968. To date, our medical teams have performed more than
1,200 heart transplants.
Our multidisciplinary program includes:
- Specialists in heart failure management and heart
transplantation
- Experts in cardiothoracic surgery
- State-of-the-art diagnostic tests from radiologists, molecular
biologists and pathologists
- Access to new clinical trials
in heart failure and heart transplantation
Innovations introduced in the transplant field from Stanford include:
- The operative method for heart transplantation
- The
use of percutaneous, transvenous biopsy of the heart to detect
rejection
- The use of new immunosuppressive drugs, including
cyclosporine, to prevent rejection
- The first successful
heart-lung transplantation procedure
- The first successful
use of a mechanical device or
left
ventricular assist device (LVAD) as a bridge-to-heart
transplantation
- The development of
intravascular
ultrasound (IVUS) to detect early evidence of transplant
coronary
artery disease
- The use of peripheral
blood gene expression testing to identify patients at low risk for
rejection, allowing doctors to safely decrease the number of
biopsies performed
Approximately 40 to 50 patients undergo heart transplantation each
year at Stanford. The procedures are performed in patients from
newborns to adults over 60 years of age. Almost every type of
end-stage heart disease has been treated here, and the Stanford team
remains a leader in introducing new concepts and treatments to improve
outcomes for transplant patients.